Physicians' Academy for Cardiovascular Education

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

Direct effects of iron on human cardiomyocytes

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Harmful effects of alcohol and smoking on arterial system in adolescents

3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

Can sex-specific thresholds for hs-troponin improve diagnosis of myocardial infarction?

3' education - Aug. 28, 2018 - Prof. Nicholas Mills, Edinburgh, UK

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

Greater reduction in SBP with church-based lifestyle intervention in black communities

Literature - Oct. 19, 2018 - Schoenthaler AM et al. - Circ Cardiovasc Qual Outcomes 2018

A community-based lifestyle intervention resulted in greater SBP reduction when compared with health education alone in hypertensive blacks, as observed in the FAITH randomized trial.

Virtual histology does not reveal PCSK9 inhibition-induced changes in plaque composition

Literature - Oct. 18, 2018 - Nicholls SJ et al. - J Am Coll Cardiol. 2018

In a substudy of GLAGOV, IVUS-based virtual histology showed regression of coronary atherosclerosis in evolocumab-treated patients, but no changes in plaque composition as compared with placebo.

GLP-1 receptor agonist therapy associated with decreased CV risk in T2DM patients with CKD

Literature - Oct. 18, 2018 - Mann JFE et al. - Circulation 2018

In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes in patients with type 2 diabetes and chronic kidney disease at high CV risk.

GLP-1 receptor agonist therapy associated with decreased CV risk in T2DM patients with CKD

Literature - Oct. 17, 2018 - Mann JFE et al. - Circulation 2018
In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.

In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.

PCSK9-antibodies do not significantly affect balance cholesterol synthesis and absorption

Literature - Oct. 17, 2018 - Silbernagel G et al. - J Lipid Res 2018

PCSK9-antibodies reduce non-cholesterol sterols but they do not significantly affect the balance between cholesterol synthesis and absorption, irrespective of cholesterol-lowering pretreatment.

Practical guidance on implementation of ESC recommendations on management of iron deficiency in chronic HF

News - Oct. 16, 2018

Despite specific recommendations on its management in the 2016 ESC Heart Failure Guidelines, iron deficiency is insufficiently diagnosed and treated in clinical practice. Practical guidance is now provided to complement the ESC Guidelines.

SGLT2 inhibition may improve survival of high risk T2DM patients

Literature - Oct. 16, 2018 - Claggett B et al. - Circulation. 2018

Actuarial methods to estimate survival suggest that survival in T2DM patients with established CVD improves with empagliflozin compared with placebo.

U-Prevent helps predict individual effect of medication on CVD

News - Oct. 16, 2018

The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.

High Lp(a) levels associated with increased CV risk despite statin treatment

Literature - Oct. 16, 2018 - Willeit P et al. - The Lancet 2018
Meta-analysis of individual-patient data shows that elevated Lp(a) levels of 50 mg/dL or higher were associated with an increased hazard ratio of CV events, independent of other risk factors and statin or placebo treatment.

Meta-analysis of individual-patient data shows that elevated Lp(a) levels of 50 mg/dL or higher were associated with an increased hazard ratio of CV events, independent of other risk factors and statin or placebo treatment.

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

New genomic risk score improves prediction of coronary artery disease

Literature - Oct. 15, 2018 - Inouye M et al. - J Am Coll Cardiol 2018

A new genomic score provides the opportunity to stratify individuals with different trajectories of CAD risk in general populations and to perform genomic screening in early life.

IL-6 receptor antagonism modifies PCSK9 levels in NSTEMI patients with hypercholesterolemia

Literature - Oct. 15, 2018 - Ueland T et al. - Open Heart 2018

In patients with an established diagnosis of hypercholesterolemia, tocilizumab blunted the NSTEMI-associated PCSK9 increase and this was strongly correlated with a decrease in neutrophil numbers.